ʱÓñô³Oncogene·¢ÏÖÄÒÅݵĴÙÖ×Áöй¦ÄÜ
5ÔÂ3ÈÕ£¬¹ú¼ÊÆÚ¿¯Oncogene ÔÚÏß·¢±íÁËÖйú¿ÆÑ§ÔºÉϺ£ÉúÃü¿ÆÑ§Ñо¿Ôº/ÉϺ£½»Í¨´óѧҽѧԺ½¡¿µ¿ÆÑ§Ñо¿ËùʱÓñô³Ñо¿×éÌâΪTumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities µÄÑо¿³É¹û£¬²ûÊöÁËÖ×Áöϸ°ûµÄ·ÖÃÚÄÒÅÝÔÚÓÕµ¼¼ä³äÖʸÉϸ°û´ÙÖ×ÁöÉú³¤·½ÃæµÄÖØÒª×÷ÓÃÒÔ¼°Ïà¹Ø»úÖÆ¡£
¼ä³äÖʸÉϸ°û¾ßÓÐÏòÖ×ÁöÇ÷»¯µÄÌØÐÔ£¬ÒѾ±»Ö¤Êµ¿ÉÒÔͨ¹ý·ÖÃÚÉú³¤Òò×Ó¡¢Ç÷»¯Òò×Ӻͱí´ïÃâÒßµ÷½ÚÒò×ӵȣ¬´Ù½øÑª¹ÜÉú³É£¬µ÷½ÚÖ×ÁöÃâÒß΢»·¾³£¬Ó°ÏìÖ×ÁöÉú³¤¡£Ê±Óñô³Ñо¿×éÔÚǰÆÚÑо¿ÖÐÒÑ·¢ÏÖ£¬Ïà±È¹ÇËè¼ä³äÖʸÉϸ°û£¬Ö×Áö¼ä³äÖʸÉϸ°û¾ßÓÐÏÔÖøµØ´Ù½øÖ×ÁöÉú³¤µÄ×÷Óá£ÕâЩÖ×Áö¼ä³äÖʸÉϸ°ûͨ¹ý·ÖÃÚ´óÁ¿µÄÇ÷»¯Òò×Ó£¨CCL-2£¬CCL-7£¬CCL-12£©£¬ÕÐļµ¥ºËϸ°û¡¢¾ÞÊÉϸ°ûÔÚÖ×Áö²¿Î»µÄ¾Û¼¯£¬ËÜÔìÖ×ÁöÃâÒßÒÖÖÆ»·¾³£¬´Ù½øÖ×ÁöÉú³¤¡£Ö×Áö¼ä³äÖʸÉϸ°ûµÄÕâÐ©ÌØÕ÷µÄ»ñµÃÓëÖ×Áö΢»·¾³´æÔÚÃÜÇÐÁªÏµ¡£Í¬Ê±£¬Ö×Áö¼ä³äÖʸÉϸ°û¿ÉÒÔ½øÒ»²½¡°Í¬»¯¡±Ðµ½´ïÖ×Áö²¿Î»µÄ¹ÇËè¼ä³äÖʸÉϸ°û£¬Ê¹Æä¾ßÓÐÓëÖ×Áö¼ä³äÖʸÉϸ°ûÏàËÆµÄÌØÕ÷£¬²¢»ñµÃ´Ù½øÖ×ÁöÉú³¤µÄÄÜÁ¦¡£È»¶ø£¬Ö×Áö¼ä³äÖʸÉϸ°ûµÄ³õʼÐγɹý³ÌÒÔ¼°Ïà¹ØµÄ²ÎÓëÒòËØ£¬ÈÔȱ·¦Ïà¹ØµÄÑо¿¡£
²©Ê¿Ñо¿Éú¶ÅÀèÃ÷ºÍÁÖÁ¼ÓîÔÚÑо¿Ô±Ê±Óñô³ºÍÍõÓ¨µÄÖ¸µ¼Ï·¢ÏÖ£¬Ö×ÁöÔÚ·¢Éú·¢Õ¹¹ý³ÌÖУ¬»á²úÉú´óÁ¿µÄÄÒÅÝ£¨exosomes£©£¬ÕâЩÄÒÅÝ¿ÉÒÔ±»¼ä³äÖʸÉϸ°ûÉãÈ¡£¬µ÷¿Ø¼ä³äÖʸÉϸ°ûÖÐÇ÷»¯Òò×Ó£¨CCL-2£¬CCL-7£¬CCL-12£©µÄ±í´ï¡£Ïà±ÈÓÚÕý³£µÄ¼ä³äÖʸÉϸ°û£¬Ö×ÁöÄÒÅÝ´¦Àí¹ýµÄ¼ä³äÖʸÉϸ°ûÄܹ»ÕÐļ¸ü¶àµÄ¾ÞÊÉϸ°ûÏòÖ×Áö²¿Î»Ç¨ÒÆ£¬´Ù½øÖ×ÁöÃâÒßÒÖÖÆ»·¾³Ðγɣ¬´Ù½øÖ×ÁöµÄÉú³¤¡£µ±×è¶Ï¾ÞÊÉϸ°ûµÄÇ¨ÒÆ»òÕß³ýȥʵÑéСÊóÌåÄڵľÞÊÉϸ°ûºó£¬Ö×ÁöÄÒÅÝ´¦Àí¹ýµÄ¼ä³äÖʸÉϸ°ûµÄ´ÙÖ×ÁöÄÜÁ¦´ó´ó¼õµÍ¡£ÕâÒ»·¢ÏÖ±íÃ÷£¬Ö×Áöϸ°ûËù²úÉúµÄÄÒÅÝÔÚÓÕµ¼Õý³£×éÖ¯¼ä³äÖʸÉϸ°ûÏò´ÙÖ×Áö¼ä³äÖʸÉϸ°ûÑÝ»¯ÖÐÆðµ½ÁËÖØÒªµÄ×÷Ó㬶ԽÒʾÖ×ÁöÖмä³äÖʸÉϸ°ûµÄÀ´Ô´¾ßÓÐÖØÒªÒâÒ塣ͬʱ£¬ÕâÒ»³É¹ûΪÁ˽âÖ×Áöϸ°û¡¢¼ä³äÖʸÉϸ°û¼°ÃâÒßϸ°ûÖ®¼äµÄ½»»¥µ÷¿ØÔÚÖ×ÁöÖеÄ×÷ÓÃÌṩÁËеÄÊӽǺͻúÖÆ¡£
¸Ã¹¤×÷µÃµ½Á˿Ƽ¼²¿¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðί¡¢Öйú¿ÆÑ§ÔººÍÉϺ£ÊпÆÎ¯µÄÏà¹Ø×ÊÖú¡£
ÔÎÄÕªÒª£º
Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities
Mesenchymal stromal cells (MSCs) are a major component of the tumour microenvironment. A plethora of elegant studies focusing on tumour-derived MSCs have shown that they, unlike normal MSCs in other tissue, exhibit a strong ability to promote tumour progression. However, the mechanisms underlying the conversion of normal MSCs into tumour-associated MSCs are unknown. We report here a critical role of tumour cell-derived exosomes in endowing bone marrow-derived MSCs (BM-MSCs) with a tumour-favourable phenotype. Tumour cell-derived exosomes affected neither the growth factor production nor the immunosuppressive property of MSCs; rather, they endowed MSCs with a strong ability to promote macrophage infiltration into B16-F0 melanoma or EL-4 lymphoma. Ablation of macrophages by clodronate liposome administration reversed the tumour-promoting effect of MSCs educated by tumour cell-derived exosomes (TE-MSCs) on the tumour growth. By comparing the chemokine profile of BM-MSCs with that of TE-MSCs, we found that TE-MSCs produced a large amount of CCR2 ligands, CCL2 and CCL7, which are responsible for macrophage recruitment. CCR2-specific inhibitor was found to block the tumour-promoting effect of TE-MSCs. Thus, our investigations demonstrated that tumour cell-derived exosomes confer BM-MSCs the ability to enhance tumour growth. Therefore, we uncovered a novel mechanism underlying the conversion of normal MSCs to tumour-associated MSCs.